Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

Video

In Partnership With:

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering (MSK) Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Smith says that he spends most of his time in the laboratory, where he makes novel CAR T-cell designs that are aimed at increasing persistence. In myeloma, the CAR T-cell therapy with the most data is bb2121, which has been studied in the relapsed population in US-based clinical trials.

Another novel therapy is JCARH125, which is progressing in clinical trials now, although the results have yet to be reported. JCARH125 is a human-derived CAR T-cell therapy, which may limit the patient's immune response against the CAR T cell, Smith explains.

Other things that are being looked at for the next generation of CAR T-cell therapies include targeting more than 1 target with the same CAR vector. At MSK, Smith and his colleagues have created “armored CAR T cells,” which are modified to not only encode for the CAR, but also for a second gene that encodes a protein. This gives the T cells a further advantage to eradicate the myeloma in the immunosuppressive microenvironment, Smith says.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD